COVID-19 and Pregnancy

Rasmussen, Sonja A.; Jamieson, Denise J.

doi:10.1016/j.idc.2022.01.002

Cited by 32 publications

(38 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of baricitinib led to an increase in serum creatinine concentration by an average of 3.8 mmol / l after 2 weeks of treatment compared with placebo, in the future this indicator remained stable until the 104th week of treatment (Rasmussen, & Jamieson, 2022). This may be due to the inhibition of creatinine secretion by baricitinib in the renal tubules.…”

Section: Description and Pharmacological Effect Of The Drugmentioning

confidence: 93%

“…Consequently, the effect of SARS-CoV-2 infection on the fetus in the first or second trimester, or in patients with moderate or severe infection is unknown. SARS infection during pregnancy can cause premature birth, intrauterine growth restriction, intrauterine death, and the death of a newborn (Rasmussen & Jamieson, 2022). Given that the probability and exact mechanisms that allow SARS-CoV-2 to cause severe obstetric and neonatal adverse outcomes are unknown, much more medical practice and data collection on such patients, as well as further studies, and careful screening of suspected cases during pregnancy, as well as long-term monitoring of mothers and their newborns are needed.…”

Section: Treatment Of Pregnant Women With Covid-19 In Chinamentioning

confidence: 99%

“…One of the drugs that they decided to use for the treatment of pregnant women with COVID-19 was Baricitinib. Baricitinib is a drug for the treatment of rheumatoid arthritis, the evaluation of its use for the treatment of COVID-19 in pregnant women is discussed further (Taylor et al, 2017;Alzamora et al, 2020;Nana & Nelson-Piercy, 2021;Rasmussen & Jamieson, 2022;Schendrigin et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Treatment of Pregnant Women with COVID-19 Using the Drug Baricitinib

Salbieva¹,

Cheldieva²,

Plieva³

et al. 2022

J Biochem Technol

View full text Add to dashboard Cite

This article discusses the complexities and various aspects related to the treatment of pregnant women with COVID-19. The experience of Chinese doctors who were the first to face this problem is considered, and a new method of treating the disease using the drug Baricitinib is also considered. Baricitinib is an anti-inflammatory drug, a representative of the Janus kinase class, used in the treatment of rheumatoid arthritis. It blocks intracellular signaling pathways, which leads to the regulation of the synthesis of interleukins 2, 6, 10, and interferon-gamma. The drug is licensed for the treatment of rheumatoid arthritis, has good efficacy and safety indicators. Attention was paid to the doses and modes of use of baricitinib. The article discusses a study conducted by Chinese doctors. The study involved 34 infected pregnant women, of whom half were offered standard treatment and the other half standard treatment with baricitinib. In order to have a complete picture that allows us to conclude that this method of treatment is ineffective or effective, it is necessary to continue monitoring patients who took baracitinib in the treatment of COVID-19.

show abstract

Section: Description and Pharmacological Effect Of The Drugmentioning

confidence: 93%

Section: Treatment Of Pregnant Women With Covid-19 In Chinamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Treatment of Pregnant Women with COVID-19 Using the Drug Baricitinib

Salbieva¹,

Cheldieva²,

Plieva³

et al. 2022

J Biochem Technol

View full text Add to dashboard Cite

show abstract

“…However, to date, there are no data supporting an increased susceptibility to SARS-CoV-2 due to pregnancy. Nevertheless, the risk of death in pregnant women with COVID-19 is significantly increased[ 35 ]. There is also a nonlinear association between ambient temperature and the risk of infection with SARS-CoV-2.…”

Section: Sars-cov-2mentioning

confidence: 99%

Interferon-lambda: New functions on intestinal symptoms in COVID-19

Pan¹,

Wang²,

Yang³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

The tremendous public health and economic impact of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a huge challenge globally. There is increasing evidence that SARS-CoV-2 induces intestinal infections. Type III interferon (IFN-λ) has an antiviral role in intestinal infection, with focused, long-lasting, and non-inflammatory characteristics. This review presents a summary of the structure of SARS-CoV-2, including its invasion and immune escape mechanisms. Emphasis was placed on the gastrointestinal impact of SARS-CoV-2, including changes to the intestinal microbiome, activation of immune cells, and inflammatory responses. We also describe the comprehensive functions of IFN-λ in anti-enteric SARS-CoV-2 infection, and discuss the potential application of IFN-λ as a therapeutic agent for COVID-19 with intestinal symptoms.

show abstract

“…Current research on public health complications due to the continuity of limitations and social isolation caused by the Coronavirus disease 2019 (COVID-19) pandemic showed reductions in physical activity and maintenance of smoking habits, elements that increase the risk of numerous pathologies and pregnancy disorders [ 48 , 49 ]. One example is that a sedentary lifestyle and no physical activity may enhance anxiety and depression in expectant mothers [ 50 ] and neonatal complications [ 51 ] potentially making these conditions worse. Added to this socially rooted pattern is the difficulty in promoting and supporting PA while limiting the risk of COVID-19; it is a challenge to maintain adequate levels of PA and reduce cigarette smoking during a pandemic [ 52 ].…”

Section: Introductionmentioning

confidence: 99%

A Virtual Exercise Program throughout Pregnancy during the COVID-19 Pandemic Modifies Maternal Weight Gain, Smoking Habits and Birth Weight—Randomized Clinical Trial

Silva-José

Sánchez-Polán

Barakat

et al. 2022

JCM

View full text Add to dashboard Cite

The intrauterine environment is key to health from a short- and long-term perspective. Birth weight is an important indicator that may influence the fetal environment due to epigenetics. Considering physical inactivity, in parallel with higher levels of stress, affecting smoking patterns and the physical and emotional health of the pregnant population, maintaining the health of future generations is crucial. A randomized clinical trial (NCT04563065) was conducted. One-hundred and ninety-two healthy pregnant individuals were assigned to the intervention (IG) or control (CG) group. Overall, significant differences were found between groups when stratified by birth weight (χ2 (1) = 6.610; p = 0.037) with low birth weight and macrosomia found more often in the CG (4% vs. 14% and 3% vs. 9%, respectively) and higher admissions to the neonatal intensive care unit (χ2 (1) = 5.075; p = 0.024) in the CG (20/28.6%) compared to the IG (9/13.0). Smoking during pregnancy was also found more often in the CG (12/17.1%) compared to the IG (3/4.4%) (p = 0.016). A virtual program of supervised exercise throughout pregnancy during the ongoing pandemic could help to maintain adequate birth weights, modify maternal smoking habits, and lower admissions to the neonatal intensive care unit.

show abstract

COVID-19 and Pregnancy

Cited by 32 publications

References 53 publications

Evaluation of the Treatment of Pregnant Women with COVID-19 Using the Drug Baricitinib

Evaluation of the Treatment of Pregnant Women with COVID-19 Using the Drug Baricitinib

Interferon-lambda: New functions on intestinal symptoms in COVID-19

A Virtual Exercise Program throughout Pregnancy during the COVID-19 Pandemic Modifies Maternal Weight Gain, Smoking Habits and Birth Weight—Randomized Clinical Trial

Contact Info

Product

Resources

About